Figure 3: Long-Term, High-Dose Treatment of 24-Week-Old

(A) Representative ratiometric JC-1 fluorescence recorded in myocytes from a PMO-treated mouse and an untreated mdx mouse before and after exposure to 10 μM BayK(–) ± 15 μM nisoldipine (Nisol) under calcium-free conditions (0 mM Ca2+). Arrow indicates addition of drugs. (B) Mean ± SEM of JC-1 fluorescence for all myocytes exposed to drugs as indicated. (C) Representative traces of flavoprotein fluorescence recorded in myocytes from a PMO-treated mouse and an untreated mdx mouse before and after exposure to 10 μM BayK(–) ± 15 μM nisoldipine (Nisol). Arrow indicates addition of drugs. (D) Mean ± SEM of flavoprotein fluorescence for all myocytes exposed to drugs as indicated. BayK(+) = 10 μM; FCCP = 50 μM carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone; NaCN = 40 mM sodium cyanide; PMO treatment = 40 mg/kg PMO 3× per week for 19 weeks; Oligo = 20 μM oligomycin; other abbreviations as in Figure 1.

Categories

License

Elsevier user license